Screening for Renal Cell Carcinoma in End-Stage Renal Disease Patients

Risk Factors and Screening Recommendations

The American College of Oncology recommends screening for renal cell carcinoma in patients with end-stage renal disease who have been on long-term dialysis (>10 years), those with acquired renal cystic disease, and those who have had kidney transplantation 1, 2, 3
Kidney transplant recipients have an elevated risk of RCC development, according to the American College of Oncology 3
Patients with tuberous sclerosis syndrome should be screened for renal cell carcinoma, as recommended by the American College of Oncology 1, 2

Ultrasonography is the initial imaging modality of choice for screening, as recommended by the American College of Oncology 1, 3
CT scan with contrast (if not contraindicated) should be used for further investigation of suspicious findings, according to the American College of Oncology 3
MRI may provide additional information when intravenous contrast cannot be used, as suggested by the American College of Oncology 4

Younger age at diagnosis should raise suspicion for hereditary RCC syndromes, according to the European Urology Association 5
The median age of diagnosis for hereditary RCC is 37 years, compared to 64 years for sporadic cases, as reported by the European Urology Association 5
Regular surveillance is essential as ESRD patients have ongoing risk for developing RCC, as emphasized by the American College of Oncology 3

End-stage renal disease (ESRD) patients have a significantly higher incidence of renal cell carcinoma (RCC) than the general population, with studies showing rates of 1.68% in dialysis patients compared to approximately 3% in the general population 6
While hypertension, obesity, and tobacco use are established risk factors for RCC in the general population, they are not specific indications for screening in ESRD patients, according to the European Urology guidelines 6

Relying solely on general RCC risk factors (hypertension, obesity, smoking) without considering ESRD-specific risk factors may lead to inappropriate screening decisions, as stated by the European Urology guidelines 6